MedPath

Auspex Pharmaceuticals, Inc.

Auspex Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2001-01-01
Employees
35
Market Cap
-
Website
http://www.auspexpharma.com

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

Phase 1
Completed
Conditions
TOURETTE SYNDROME
Interventions
First Posted Date
2016-02-04
Last Posted Date
2021-11-09
Lead Sponsor
Auspex Pharmaceuticals, Inc.
Target Recruit Count
23
Registration Number
NCT02674321
Locations
🇺🇸

Teva Investigational Site #101, Houston, Texas, United States

Addressing Involuntary Movements in Tardive Dyskinesia

Phase 3
Completed
Conditions
Tardive Dyskinesia
Interventions
Drug: Placebo
First Posted Date
2014-11-17
Last Posted Date
2021-11-09
Lead Sponsor
Auspex Pharmaceuticals, Inc.
Target Recruit Count
298
Registration Number
NCT02291861
Locations
🇺🇸

Teva Investigational Site 154, Baltimore, Maryland, United States

🇺🇸

Teva Investigational Site 168, Burlington, Vermont, United States

🇺🇸

Teva Investigational Site 160, Irvine, California, United States

and more 103 locations

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

Phase 3
Completed
Conditions
Tardive Dyskinesia
Interventions
Drug: Placebo
First Posted Date
2014-07-24
Last Posted Date
2022-04-01
Lead Sponsor
Auspex Pharmaceuticals, Inc.
Target Recruit Count
343
Registration Number
NCT02198794
Locations
🇺🇸

Teva Investigational Site 144, Port Charlotte, Florida, United States

🇺🇸

Teva Investigational Site 130, Oceanside, California, United States

🇺🇸

Teva Investigational Site 145, Tuscaloosa, Alabama, United States

and more 79 locations

Aim to Reduce Movements in Tardive Dyskinesia

Phase 2
Completed
Conditions
Tardive Dyskinesia
Interventions
Drug: Placebo
First Posted Date
2014-07-21
Last Posted Date
2021-11-09
Lead Sponsor
Auspex Pharmaceuticals, Inc.
Target Recruit Count
117
Registration Number
NCT02195700

Alternatives for Reducing Chorea in Huntington Disease

Phase 3
Completed
Conditions
Chorea Associated With Huntington Disease
Interventions
First Posted Date
2013-07-12
Last Posted Date
2021-11-09
Lead Sponsor
Auspex Pharmaceuticals, Inc.
Target Recruit Count
119
Registration Number
NCT01897896
Locations
🇺🇸

Teva Investigational Site 057, Birmingham, Alabama, United States

🇺🇸

Teva Investigational Site 052, Englewood, Colorado, United States

🇺🇸

Teva Investigational Site 093, Toledo, Ohio, United States

and more 35 locations
© Copyright 2025. All Rights Reserved by MedPath